Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin, which has the unique property of polymerizing when deoxygenated. The pathophysiology of acute and chronic clinical manifestations of SCD have shown the central role of dense, dehydrated red cells in acute and chronic clinical manifestations of this pathology. Recent studies have indicated that SCD is characterized by a hypercoagulable state that contributes to the vaso-occlusive events in microcirculation, leading to acute and chronic sickle cellrelated organ damage. This review discusses, in the context of SCD, (1) abnormalities in the coagulation system, (2) perturbation of platelet activation and aggregation, (3) vascular endothelial dysfunction, (4) the contribution of cell inflammatory responses, and (5) the connection with nitric oxide metabolism. We also review the available studies on the therapeutic approaches in clinical management of hypercoagulability in SCD.
Sickle cell disease (SCD; Online Mendelian
Inheritance in Man [OMIM] No. 603903) is an autosomal recessive genetic red cell disorder with a worldwide distribution that results from a point mutation (b S , 6V) in codon 6, with the insertion of valine in place of glutamic acid, leading to the production of a defective form of hemoglobin (hemoglobin S [HbS] ). In the United States 75,000 people have SCD. In Europe, immigration from developing countries has increased the prevalence of SCD through the second half of the 20th century, and now almost 20,000 to 25,000 SCD patients have been registered. [1] [2] [3] [4] Sickle hemoglobin (HbS) shows peculiar biochemical properties, polymerizing when deoxygenated. Studies of the kinetics of HbS polymerization following deoxygenation have shown that the kinetics of polymer formation is a high-order exponential function of hemoglobin concentration, thus demonstrating the crucial role of cellular HbS concentration in the phenomenon of sickling. 5, 6 HbS polymerization is associated with a reduction in cell ion and water content (cell dehydration), increased red cell density, and further acceleration of HbS polymerization. [5] [6] [7] Pathophysiological studies have shown that the dense, dehydrated red cells play a central role in acute and chronic clinical manifestations of SCD, in which intravascular sickling in capillaries and small vessels leads to vaso-occlusive and impaired blood flow. 6, 8 The persistent membrane damage associated with HbS polymerization also favors the generation of distorted rigid cells and further contributes to vaso-occlusive events and cell destruction in the peripheral circulation. These damaged dense sickle red cells also show a loss of phospholipid asymmetry with externalization of phosphatidylserine (PS; Fig. 1 ), which is believed to play a significant role in promoting macrophage recognition with removal of THROMBOSIS AND SICKLE CELL DISEASE/FRANCESCHI ET AL erythrocytes (erythrophagocytosis) and activation of coagulation. Setty et al have recently shown that increased PS-exposing red cells are associated with thrombin generation as well as increased tissue factor (TF) expression, more likely due to the increased circulating hemoglobin than as a direct connection between PS-exposing red cells and vascular endothelium. [9] [10] [11] A complex perturbation of hemostasis has been reported in SCD both under steady state and during acute events. The vaso-occlusive events in the microcirculation result from a complex and still partially known scenario involving the interactions among different cell types, including dense, dehydrated sickle cells, reticulocytes, abnormally activated endothelial cells, leukocytes, platelets, and plasma factors such as coagulation system, cytokines and oxidized proinflammatory lipids. [12] [13] [14] [15] [16] [17] [18] [19] [20] Clinical manifestations of the prothrombotic state of sickle cell patients include venous thromboembolism, in situ thrombosis, and stroke, associated with an higher risk of thrombotic complications in patients splenectomized or with functional hyposplenism. 6, [21] [22] [23] [24] [25] [26] [27] COAGULATION SYSTEM AND SICKLE CELL DISEASE Studies in SCD have shown increased prothrombin fragment 1.2 (F1.2), thrombin-antithrombin complexes, plasma fibrinogen products, D-dimer, and decreased factor V, suggesting an enhanced thrombin generation and supporting a chronic thrombophilic state in SCD patients that is further amplified during acute events (Table 1) . 13, 17, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Sickle cell patients also show abnormal (decreased) levels of factor (F) VII and activated FVII compared with normal subjects, most likely due to increased TF activity that promotes accelerated FVII turnover.
37,39 Moreover, in sickle cell patients under steady state conditions, decreased FXII and FIX have been observed, possibly related to activation of the intrinsic coagulation pathway 40 (Table 1) . Ataga et al recently reported high levels of thrombin-antithrombin complex, prothrombin fragment F1 þ 2, and D-dimer, associated with an activation profile of vascular endothelium (i.e., soluble vascular endothelial cell adhesion molecule) in sickle cell subjects with pulmonary hypertension compared with normal controls. 41 It is interesting to note that these authors also observed a correlation between the rate of hemolysis and the hypercoagulability state in SCD patients with pulmonary hypertension. 41 However, in another cohort of SCD patients with mild pulmonary hypertension, van Beers et al reported no association of the hypercoagulative state of SCD with the early phase of pulmonary hypertension, 42 suggesting that more complex events are involved in the pathogenesis of pulmonary hypertension in SCD. 64 Browne et al, 65 Wun et al, 69 Famodu and Oduwa, 70 Lee et al 71 Platelet aggregation Increased Kenny et al, 66 Westwick et al, 67 Studies on natural anticoagulant in patients with SCD showed low levels of protein C and S, suggesting a possible perturbation in either their synthesis related to liver disease or a consumption by increased TF and thrombin production. The relative deficiency of protein C and S was reported to have a clinical impact on the risk of developing stroke in children with SCD.
33,34,38,45-47
However, variable levels of protein S and C were observed in sickle cell patients during acute events compared with steady state, suggesting a more complex biological scenario. 33, 34, 38, [45] [46] [47] In addition, the increased percentage of circulating sickle red cells exposing PS might bind protein S, most likely contributing to protein S reduction.
48,49
The prothrombotic state of SCD is also associated with abnormalities in the fibrinolytic system, mainly characterized by increased plasma levels of plasminogen activator inhibitor (PAI)-1 in both steady state and during sickle acute events compared with the normal population. 36, 38, 50, 51 Because the synthesis of PAI-1 is increased in activated or damaged endothelial cells and also secreted by activated platelets, 52 the increased PAI-1 levels in sickle cell patients suppressing the normal fibrinolytic system might participate in the pathogenesis of vaso-occlusive events in SCD. Although studies have been performed on coagulation system activation during acute events in SCD, inconclusive data have been reported thus far. 34, 36, 38, 53, 54 Studies on thrombophilic deoxyribonucleic acid mutations have been performed in patients with SCD to assess their possible impact on sickle cell thrombotic events. Factor V Leiden and the prothrombin variant (FII G20210A) have been evaluated in sickle cell patients of African descent. Because the frequency of these two alleles is low in the African descendent population, the contribution of these two thrombophilic mutations on thrombotic clinical manifestation of SCD seems to be limited. [55] [56] [57] [58] However, in sickle cell patients from eastern Saudi Arabia and Lebanon, a nonsignificantly higher frequency of FII G20210A was observed compared with normal controls. 59 Moreover, an association between factor V Leiden and venous thrombotic events was shown in Iranian patients with SCD, supporting a different impact of this thrombophilic mutation within sickle cell patients from different ethnic groups. 60, 61 Studies on methylene tetrahydrofolate reductase (MTHFR) polymorphisms were performed in patients with SCD, but no association between any MTHFR mutation and thrombotic events was highlighted. 55, 57, 62, 63 PLATELETS AND SICKLE CELL DISEASE Studies on the role of platelets in clinical manifestations of SCD on both steady state and acute events have been partially characterized, and much still remains to be investigated (Table 1) . Increased production of thromboxane-A2 and prostaglandin metabolites associated with decreased platelet trombospondin-1 levels, suggesting a chronic activation of platelets, was shown in urine from SCD patients. 64, 65 Other studies also showed increased platelet aggregation in SCD. [66] [67] [68] Increased platelet activation markers such as P-selectin (CD62), CD63. and activated glycoprotein (GP)IIb/IIIa as well as increased plasma soluble factors as platelet factor (PF)-3, -4 and b-thromboglobulin and platelet-derived soluble CD40 ligand (sCD40L) were reported in SCD patients using a cytofluorimetric approach.
36,69-71 Villagra et al suggested that the relative reduction in nitric oxide (NO) bioavailability might participate in triggering platelet activation as well as increasing platelet adhesive properties in patients with SCD. 72 PS-rich platelets have also been described in SCD patients; these show an increased binding to annexin V that might participate in activation of the coagulation system. 36 Recently, Proença-Ferreira et al reported an increased ability of platelets from subjects with SCD to adhere to fibrinogen through modulation of platelet's cyclic adenosine monophosphate content via phosphodiesterase-3A activity associated with increased a IIb b 3-integrin activation. 73 It is interesting to note that in clinical management of SCD patients during acute pain events, the platelet count first decreases, followed by a paradoxical increase associated with higher plasma levels of the platelet products PF4 and b-thromboglobulin (bTG). This suggests a further amplification of platelet activation during acute events.
33, [74] [75] [76] The reduction in platelet content and then the rebound during resolution of acute events have been related to functional asplenia of patients with SCD. 13, 15, 65 Studies on polymorphisms of human platelet alloantigen (HPA), a complex of platelet glycoproteins with other cell-bound factors, showed a possible pro-thrombotic role in different thrombotic disorders and in sickle cell patients with cerebrovascular events. [77] [78] [79] [80] HPA polymorphisms result in platelet structural changes and/or levels of adhesion proteins. In a case-control study, Al-Subaie et al reported that the HPA-3 variant, which has an isoleucine-to-serine substitution close to the C-terminus of the GPIIb heavy chain, seems to be an independent risk factor for acute vaso-occlusive events in SCD (Table 2) . 81 However, no conclusive evidence is actually available on the real impact of thrombotic mutations in SCD mainly due to the limited number of studies and the differences in the genetic background of the sickle cell population studied.
VASCULAR ENDOTHELIUM DYSFUNCTION IN SICKLE CELL DISEASE
SCD patients have shown abnormally activated circulating endothelial cells that increase during acute vasoocclusive crisis, which is compatible with the presence of chronic vascular endothelial damage further worsening during acute events. 8, 54, [82] [83] [84] [85] Recent studies on the sickle cell-endothelium adhesive mechanism identified different interactions that may have particular relevance in the generation of acute vaso-occlusive events: (1) the integrin a a 4b b 1 receptor of fibronectin and VCAM-1, Eselectin, and P-selectin; (2) the thrombospondin (TSP) and/or collagen and receptor CD36, present on the surface of endothelial cells, platelets, and reticulocyterich subpopulations of normal and sickle erythrocytes; (3) the sulfate glycolipids, which bind TSP, VWF multimer, and laminin; 6,86,87 (4) the Lutheran blood group proteins (BCAM/LU), whose expression is increased in red cells from SCD patients as is their binding to the a5 subunit of laminin, a component of extracellular subendothelial matrix; 88, 89 (5) the ICAM-4 (Landsteiner-Weiner blood group glycoprotein), which binds aVb3 integrin receptors on endothelial cells; [90] [91] [92] [93] and (6) the exposure of PS, detectable in a subpopulation of sickle red cells, which participates in sickle cell adhesion to activated endothelium 9,94-97 ( Fig. 1) . In SCD patients, increased levels of VWF and, in particular, large VWF multimers were observed and associated with acute vaso-occlusive events. [98] [99] [100] [101] The increased levels of circulating VWF multimers are related to the activity of the metalloprotease ADAMTS 13 (a disintegrin and metalloproteinase with thrombospondin domain 13) that cleaves the hyperadhesive ultra-large VWF under conditions of high fluid shear stress, [102] [103] [104] playing an important role in maintaining the endothelial cell surface free from hyperadhesive ultra-large VWF. 105 Studt et al showed that free hemoglobin can inhibit ADAMTS 13 activity, affecting the VWF cleavage in patients with thrombocytopenic purpura. 106 Schnog et al 98 reported a decreased ADAMTS 13 activity in 112 Sebastiani et al, 113 Elliott, 116 SCD, sickle cell disease; GP, glycoprotein; VCAM, vascular cell adhesion molecule; TNF, tumor necrosis factor; IL, interleukin; NO, nitric oxide.
sickle cell patients compared with normal controls as well as an associated reduced ADAMTS 13-to-VWF antigen ratio. 99, 107 The same authors further demonstrated an inverse relationship between ADAMTS 13 activity and extracellular hemoglobin levels, suggesting that hemoglobin might compete with VWF for ADAMTS 13. This would cause a relative deficiency of ADAMTS 13, which in turn would block the proteolysis of VWF and lead to the accumulation of hyperadhesive ultra-large VWF on the vascular endothelium surface. 98, 99, 107 This mechanism might represent a new element contributing to the complex scenario of microvascular thrombosis in SCD.
Genetic modifiers with functional effects on vascular endothelium homeostasis were evaluated in few studies in patients with SCD ( Table 2 ). Taylor et al showed a protective effect from stroke of G1238C VCAM1 single nucleotide polymorphism in sickle cell patients. 108 Polymorphisms of cytokines involved in proinflammatory responses, such as tumor necrosis factor (TNF)a and interleukin (IL)4, were correlated with the risk of stroke in children with SCD. 109 Polymorphisms of either endothelin-1 (ET-1) and endothelial-NO synthase (eNOS) were linked to the susceptibility of sickle cell patients to acute vaso-occlusive events. 110, 111 Gene polymorphisms in Klotho (KL), encoding for a bglucosidase-like protein involved in endothelial NO homeostasis, were linked to stroke and osteonecrosis in SCD as well as to leg ulcers. [112] [113] [114] [115] A polymorphism of the receptor tyrosine kinase Tie, a factor involved in NO metabolism and leukocyte chemotaxis, was identified as a possible additional genetic modifier associated with leg ulcers in SCD patients. [112] [113] [114] [115] Finally, polymorphisms of genes from bone morphogenic protein signaling pathway involved in protection of the vascular endothelial surface were associated with the risk for different acute vasoocclusive events including stroke, priapism, or leg ulcers. 112, 113, 116 Although these studies show the possible role of genetic modifiers of endothelial homeostasis affecting acute vaso-occlusive events in SCD, further investigations should be performed to verify the real impact of these gene polymorphisms on larger SCD patient populations.
INFLAMMATION AND LEUKOCYTES PARTICIPATE IN SICKLE CELL VASO-OCCLUSIVE EVENTS
A chronic inflammatory state has been described in SCD patients characterized by increased plasma levels of acute phase proteins and soluble cytokines such as IL1b, IL6, TNF-a, and endothelin-1 (ET-1) that are further elevated during acute vaso-occlusive events. These factors participate in leukocyte chemotaxis, modulate vascular tone, and contribute to sickle cell-related tissue damage. 18, 20, 85, [117] [118] [119] [120] [121] [122] Recently, Enenstein et al reported an altered ratio of proinflammatory factor RelA to antiinflammatory factor KLF2 in sickle cell children with high risk of stroke, thus suggesting a complex prothrombotic network involving abnormal activated vascular endothelium and inflammation. 123 Inflammatory cells such as neutrophils were shown to participate in sickle cell-related vaso-occlusive events; these cells were able more efficiently to adhere to fibronectin and vascular endothelial cells than neutrophils from normal subjects. This phenomenon seems to be related to the higher surface expression of adhesion molecules used for transendothelial migration. 124, 125 In fact, b2 integrin Mac 1 (a M b 2 or CD11b/CD18) was reported to be increased in neutrophils from SCD patients, suggesting a higher ability of SCD neutrophils to firmly adhere to vascular endothelium surface than normal controls with local reduction of blood flow, which is crucial in the development of acute vasoocclusive events. 126, 127 Hidalgo et al reported an interesting connection between neutrophils, red blood cells, and activated endothelial surface in developing vascular occlusion and hypoxic cell damage in microcirculation of lung from a mouse model of SCD. 128 These authors hypothesized that the interaction between these blood cell types and the activated endothelium might be coordinated by the interactions of endothelial E-selectin, neutrophil E-selectin ligand (ESL)-1, and the leukocyte integrin Mac1 (a M b 2 CD11b/CD18). The heterotypic aggregates are generated by the binding of ESL-1 on neutrophils to E-selecting on the vascular endothelium, which signals the activation of Mac 1 on neutrophils and in turn mediates the heterotypic association of neutrophils with sickle red blood cells. 128 This interesting pathway, E-selectin-ESL-Mac1, should be further studied in human subjects with SCD and might be explored as a possible target to design new pharmacological strategies in treatment sickle cell-related vasoocclusive events.
Increased iNKT cells, nonphagocytic inflammatory cells producing proinflammatory cytokines were observed in SCD patients, and it was proposed that iNKT cells might contribute to SCD vasculopathy, representing a possible additional risk factor for stroke in sickle cell patients.
23,129
THE NITRIC OXIDE CONNECTION SCD is characterized by a relative reduction in NO bioavailability that contributes to abnormal endothelial activation and SCD organ damage. 14, 16, 85, 122, [130] [131] [132] NO is a potent vasodilator and inhibitor of vascular remodeling, and it also affects the multistep cascade of events involved in leukocyte, platelet, and endothelial activation. NO is generated from L-Arginine by endothelial cells via constitutive and inflammatory inducible nitric oxide synthases. Moreover, chronic hemolysis leading to increase the plasma levels of hemoglobin (i.e., an efficient NO buffer) contributes to reduce the levels of NO in SCD. Thus the NO-reduced bioavailability might contribute to the hypercoagulable state observed in patients with SCD.
ANTIPLATELET AND ANTICOAGULANT AGENTS IN SICKLE CELL DISEASE
Information regarding the use of antiplatelet agents or anticoagulants in the treatment of either acute or chronic clinical manifestation of SCD is still limited due to the small and relative low-quality design of the studies. 17, [133] [134] [135] [136] [137] [138] The impact of antiplatelet agents such as aspirin or ticlopidine on either the frequency and/or duration of acute vaso-occlusive crisis were evaluated in a few studies. 17, [133] [134] [135] [136] [137] [138] The results were not conclusive because either no differences or limited ameliorations in the frequency and duration of acute vaso-occlusive events in SCD patients were observed. 17, [133] [134] [135] [136] [137] [138] Tomer et al recently reported a reduction of pain episodes and in plasma levels of F1 þ 2, D-dimer, and the plasminantiplasmin complex in a small cohort of sickle cell patients supplemented with n-3 fatty acid, suggesting a possible correlation between a reduced prothrombotic state and the rate of acute sickle cell-related events.
29
Anticoagulant treatment with heparin has been considered as an additional therapeutic approach to block sickle cell adhesion to endothelial cells through the P-selectin pathway 132, [139] [140] [141] or binding to TSP that can mediate the interactions between sickle erythrocytes and the vascular endothelial surface. A double-blind randomized trial with tinzaparin in SCD patients during acute vaso-occlusive events documented a reduction of their severity and duration. 9, 142 Studies with a low dose of warfarin or acenocoumarol were reported to slightly reduce the frequency of acute pain events with decreased thrombin generation and fibrinolysis, however without reaching a significant clinical amelioration. This therapy was also associated with frequent bleeding complications. 98, 133, 143, 144 Thrombolytic agents in the treatment of stroke in SCD are generally precluded due to the high risk of possible hemorrhage as a complication of thrombolytic therapy in patients presenting with moya-moya disease or pseudoxanthoma elasticum tissue abnormalities.
23,145,146

CONCLUSION
The prothrombotic state in SCD contributes to acute and chronic clinical manifestations. Studies have shown abnormalities in the coagulation system, perturbation of platelet activation and aggregation, increased adherence of neutrophils, increased nonphagocytic iNKT cells, and abnormal red cells that more easily adhere on an abnormally activated vascular endothelial surface in SCD. Although progress has been made in characterizing the hypercoagulable state in this challenging disorder, more remains to be investigated, both related to the pathogenesis of vaso-occlusive events and the use of antiplatelet and anticoagulant treatments for a more effective clinical management of SCD patients. 
